First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?

Marco Airoldi,Michela Bartolini,Roberta Fazio,Sara Farinatti,Valentina Daprà,Armando Santoro,Alberto Puccini

DOI: https://doi.org/10.1007/s11912-024-01601-x

2024-10-12

Current Oncology Reports

Abstract:This narrative review explores the efficacy and applicability of anti-EGFR therapy as the first-line treatment for patients with RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC). It critically examines current guidelines, along with recent evidence in the literature, to assess whether it should be universally applied.

oncology